Alkem Laboratories Ltd

Alkem Laboratories Ltd share price declined by 0.94% to Rs 5418.75. The Company's net profit jumped 107.20% to Rs 521.49 crore, while revenue from operations slightly gained 3.80% to Rs 3740.15 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.69%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Alkem Laboratories Ltd has softened by 3.76% and 1.21% in the same period respectively. Profit before tax (PBT) of Alkem Laboratories Ltd stood at Rs 771.99 crore in Q2 FY26, easing 0.13% year-on-year, and surging by 82.57% quarter-on-quarter. EBITDA came in at Rs 613 crore, gaining 1.78% YoY and rallying 93.27% sequentially. Total expenses marginally dropped 3.68% to Rs 3074.29 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 910.02 crore, posting a minor increase of 1.69% YoY, while employee benefits expense was at Rs 808.9 crore, surging 13.59% YoY. For the TTM ended FY26, revenue from operations rose 13.48% to Rs 14712.27 crore, while net profit grew slightly 6.19% to Rs 2353.13 crore, compared to previous TTM. EBITDA jumped by 204231% to Rs 2421.86 crore, and PBT improved 13.61% to Rs 2870.89 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1963.03 crore in FY26, as against Rs 1912.84 crore in FY25. Alkem Laboratories Ltd gained 0.52% in last one year, outperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.

Alkem Laboratories Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window will open on August 17, 2026, following the communication of the company's financial results for the quarter ended June 30, 2026, to the stock exchanges on August 14, 2026.

Alkem Laboratories Limited announced the appointment of Mr. Rajpal Singh Rana to a senior management position, effective August 3, 2026, according to a regulatory filing. Mr. Rana, who possesses over 30 years of experience in marketing and sales within the pharmaceutical sector, joins Alkem as Senior Vice President - Marketing & Sales, Acute Cluster, and holds an MBA in Marketing from Sikkim Manipal University and a B.Sc. from Delhi University.

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2026.

Alkem Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 17 August 2026.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5680, up 1.46% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.16% on the day, quoting at 24468.6. The Sensex is at 78452.78, up 0.21%. Alkem Laboratories Ltd has risen around 6.04% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 6.86% in last one month and is currently quoting at 25866.25, down 0.24% on the day. The volume in the stock stood at 1.28 lakh shares today, compared to the daily average of 1.58 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 5692.5, up 1.13% on the day. Alkem Laboratories Ltd is up 18.31% in last one year as compared to a 4.13% drop in NIFTY and a 16.41% drop in the Nifty Pharma index.The PE of the stock is 29.05 based on TTM earnings ending March 26.Powered by Capital Market - Live

Alkem Laboratories announced that the 52th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Profit before exceptional items and tax jumped 40.74% YoY to Rs 557.82 crore in Q4 FY26. Exceptional items for the quarter include Rs 60.27 crore incremental liablitiy towards gratuity and leave enchasehment for past service cost following finalization of central rules under labour codes and Rs 74.7 crore towards impairment of real estate investments. EBITDA stood at Rs 517.4 crore in Q4 FY26, up 32.2% YoY. EBITDA margin improved to 14.4% in Q4 FY26 as against 12.4% in Q4 FY25. During the quarter, R&D expenses stood at Rs 229.3 crore, up 44.67% compared with Rs 158.5 crore in Q4 FY25 and accounted for 6.4% of total revenue. India sales were Rs 2,324.5 crore in Q4 FY26, YoY growth of 8.8%. International sales stood at Rs 1,222.3 crore, up 25.4% YoY. On an annual basis, the company's consolidated net profit rose 6.3% to Rs 2,301.80 crore in FY26 compared with Rs 2,165.48 crore in FY25. Revenue from operations jumped 13.48% to Rs 14,712.27 crore in FY26 compared with Rs 12,964.52 crore in FY25. Vikas Gupta, CEO of Alkem, said, 'We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26. Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.' Meanwhile, the company's board recommended a final dividend of Rs 10 per equity share of Rs 2 each for financial year ended 31st March, 2026. The company fixed record date as 7th August, 2026 for final dividend. It will be paid on and from 1st September 2026. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.Powered by Capital Market - Live

Stocks to Watch: Wipro expanded its partnership with ServiceNow to implement and scale the impact of agentic AI workflows across core enterprise functions such as IT, HR, procurement, and cybersecurity. Under this expanded partnership, Wipro will integrate Wipro Intelligence, its unified suite of AI-powered platforms, solutions, and transformative offerings, with the ServiceNow AI Platform enabling organizations to streamline the initiation, orchestration, and execution of work across enterprise systems. Alkem Laboratories reported 25.11% drop in consolidated net profit to Rs 251.11 crore despite 14.62% jump in revenue from operations to Rs 3,603.32 crore in Q4 March 2026 over Q4 March 2025. Roto Pumps reported a 55.47% decline in consolidated net profit to Rs 5.73 crore in the quarter ended 31 March 2026, compared with Rs 12.87 crore posted in the corresponding quarter last year. PC Jeweller reported 58.06% jump in standalone net profit to Rs 150.33 crore on 32.66% increase in revenue from operations to Rs 927.34 crore in Q4 FY26 over Q4 FY25. PG Electroplast reported 55.34% decline in consolidated net profit to Rs 64.86 crore in Q4 FY26 compared with Rs 145.23 crore posted in Q4 FY25. Revenue from operations dropped 10.11% YoY to Rs 1,716.67 crore in Q4 FY26. Time Technoplast has reported 20.4% rise in consolidated net profit to Rs 131.84 crore on a 14.2% increase in revenue from operations to Rs 1,676.67 crore in Q4 FY26 over Q4 FY25. Axiscades Technologies has reported 98.6% drop in consolidated net profit to Rs 0.43 crore in Q4 FY26 from Rs 30.76 crore in Q4 FY25. Revenue for the period under review rose by 1.9% year-on-year (YoY) to Rs 273.01 crore during the period under review. Gulf Oil Lubricants India has reported 3.44% drop in consolidated net profit to Rs 89.59 crore despite a 10.76% increase in revenue from operations to Rs 1,055.26 crore in Q4 FY26 over Q4 FY25.Powered by Capital Market - Live

Net profit of Alkem Laboratories declined 22.69% to Rs 236.46 crore in the quarter ended March 2026 as against Rs 305.86 crore during the previous quarter ended March 2025. Sales rose 14.62% to Rs 3603.32 crore in the quarter ended March 2026 as against Rs 3143.75 crore during the previous quarter ended March 2025. For the full year,net profit rose 6.30% to Rs 2301.80 crore in the year ended March 2026 as against Rs 2165.48 crore during the previous year ended March 2025. Sales rose 13.48% to Rs 14712.27 crore in the year ended March 2026 as against Rs 12964.52 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3603.323143.75 15 14712.2712964.52 13 OPM %14.3612.45 -20.4319.38 - PBDT663.58508.83 30 3427.782884.19 19 PBT557.82396.34 41 3045.722527.03 21 NP236.46305.86 -23 2301.802165.48 6 Powered by Capital Market - Live